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To the Editor: I read with great interest the letters by Wan
et al.1 and Garg.2
The authors discussed the possibility and consequences of
labeling former kidney donors with estimated GFR o60 ml
per min per 1.73 m2 as chronic kidney disease patients.
According to NKF K/DOQI guidelines that established the
current classification of chronic kidney disease, it is possible
that GFR 30–59 ml per min per 1.73 m2 could also be normal
in individuals after unilateral nephrectomy.3 Therefore
‘chronically decreased GFR’ could be the more appropriate
term to name the condition of these subjects in the absence of
any additional marker of kidney damage.
Both authors agree about the possibility of increased
cardiovascular risk in these patients and then emphasis
the need of research on the prognostic significance of a
reduced estimated GFR in this population. We recently
studied the frequency and severity of coronary artery
calcification in 101 former kidney donors to test the
hypothesis that decreased GFR is associated with increased
coronary artery calcification.4 The median post nephrectomy
duration was 64.7 months and mean GFR was 75 ml per min
per 1.73 m2. The frequency or severity of coronary artery
calcification was not increased in these former kidney donors.
These results could be at least partially reassuring the safety
of kidney donation in carefully selected donors. Certainly,
this reassurance should not shadow the importance of
healthy life style behavior and yearly regular follow-ups after
kidney donation.
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We welcome Dr Seyahi’s1 contribution to the uncertainty
surrounding the impact of mildly reduced kidney function
on future cardiovascular risk. This debate has been
generated by numerous large retrospective observational
studies. These studies are unable to determine if the
observed association between mildly reduced glomerular
filtration rate (GFR) and cardiovascular risk is causal or is
explained by comorbid conditions that lead to kidney
damage. Studies of living kidney donors offer an oppor-
tunity to test the hypothesis that reduced GFR directly
causes cardiovascular disease, because kidney donors
have an abrupt, isolated reduction in GFR in the absence
of other major comorbid illnesses or cardiovascular
risk factors. However, the low absolute cardiovascular
event rate in these subjects after nephrectomy means that
studies to adequately test the hypothesis will require large
cohorts, more than 10 years follow-up, and appropriate
selection of control subjects. In this respect, we are sure Dr
Seyahi will acknowledge that their data on 101 kidney
donors followed for a median of 5 years showing no
coronary calcification offer some reassurance, but do
not reject the hypothesis.
Counseling patients with mildly reduced GFR will
remain difficult until these uncertainties are clarified,
and we hope that Dr Seyahi’s research will stimulate others
to analyze cardiovascular risk in kidney donors.
In the meantime, the labels ‘chronically decreased GFR’
and ‘chronic kidney disease’ are likely to seem equally
imprecise and of concern to the patient with mildly
reduced GFR.
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As we promote living kidney donor transplantation as the
preferred treatment option for kidney failure, there is now
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global consensus that we also need better estimates of any
long-term donor risks.1,2 In an often-cited Swedish study,
living kidney donors lived longer than the general
population.3 However, donors go through a rigorous
evaluation process to confirm good health, and risks
would be better estimated by comparing a group of donors
to the healthiest segment of the general population.
To our knowledge, no published study has considered
whether cardiovascular events are increased after kidney
donation.
There are a few important reasons to evaluate the risk of
cardiovascular disease. First, donors appear to have
5 mm Hg increase in blood pressure above that attributable
to normal aging;4 in the general population, every
10 mm Hg increase in systolic blood pressure or 5 mm Hg
increase in diastolic blood pressure is associated with a 1.5-
fold increase in mortality from both ischemic heart disease
and stroke. This risk extends well into the ‘normal’ range
of blood pressure. Hypertension is one of the most
important causes of cardiovascular disease worldwide,
and was noted to be higher in one donor study but not
others.4 Second, psychological stress has been associated
with premature cardiovascular disease. A small percentage
of donors experience significant anxiety from the dona-
tion,5 and from having a loved one with kidney failure.
Third, in the general population, a glomerular filtration
rate (GFR) of 60–89 mL/min has been independently
associated with premature cardiovascular disease. This
new baseline level of GFR is realized by more than half of
all kidney donors.6 Some donors go on to develop lower
levels of GFR,6 or as Dr Sehayi describes it ‘chronically
decreased GFR.’1
Dr Sehayi’s data on coronary artery calcification is
indeed reassuring. What we now need is further informa-
tion, which meets modern epidemiologic standards for
accurate risk assessment. This includes future record
linkage studies and more resource intensive, prospective
cohort studies. The ideal controls may be those individuals
identified as healthy potential donors who do not undergo
the operation. Inclusion of racially diverse, older and
genetically related donors will help define whether there
are differential effects of donation among these indivi-
duals. Such efforts will improve donor selection and the
informed consent process. As highlighted by Dr Sehayi,1
such efforts will also guide care that maintains good long-
term health for previous and future living donors.
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Block randomized trial evidencing
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To the Editor: Although the use of surrogate end points
instead of hard clinical end points for the drug FDA (Food
and Drug Administration) market authorization is currently
challenged,1 we acknowledge that the promotion of sevela-
mer over calcium phosphate binder is now based on harder
evidence than coronary calcifications, as in a randomized
trial with 37 deaths occurring in incident dialysis patients,
mortality was found borderline lower.2
It should be noted, however, that the patients were likely
vitamin D insufficient,3 but receiving 1-a-OH-vitamin D
derivatives which, when compared with cholecalciferol,
are increasing vascular calcification risk as shown by a
comparison of two German cohorts of young adults with
childhood onset of end-stage renal disease:4 in Heidelberg,
the prevalence of coronary calcification was 92%, whereas
in East Berlin it was 10%, the main therapeutical difference
being a 35-fold lower cumulative dose of potentiated vitamin D
yielding. In addition, a better parathyroid suppression
(150 vs 360 pg ml1 of intact parathyroid hormone) was
observed in Berlin.
Therefore, to actually establish a superiority of sevelamer
over calcium phosphate binder, a larger trial should compare
two strategies: sevelamerþ potentiated vitamin D with
cholecalciferolþCaCO3.
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